Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
AbbVie Inc is a drug manufacturers—general business based in the US. AbbVie shares (ABBV) are listed on the NYSE and all prices are listed in US Dollars. AbbVie employs 47,000 staff and has a trailing 12-month revenue of around USD$36.2 billion.
Since the stock market crash in March caused by coronavirus, AbbVie's share price has had significant negative movement.
Its last market close was USD$86.27, which is 9.15% down on its pre-crash value of USD$94.96 and 37.92% up on the lowest point reached during the March crash when the shares fell as low as USD$62.55.
If you had bought USD$1,000 worth of AbbVie shares at the start of February 2020, those shares would have been worth USD$783.68 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,048.18.
|Latest market close||USD$86.27|
|52-week range||USD$62.55 - USD$101.28|
|50-day moving average||USD$89.87|
|200-day moving average||USD$90.5352|
|Wall St. target price||USD$109.12|
|Dividend yield||USD$4.72 (5.34%)|
|Earnings per share (TTM)||USD$4.523|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-10-13)||-1.78%|
|1 month (2020-09-18)||-4.26%|
|3 months (2020-07-20)||-13.33%|
|6 months (2020-04-20)||2.71%|
|1 year (2019-10-18)||12.83%|
|2 years (2018-10-19)||-1.93%|
|3 years (2017-10-20)||-10.23%|
|5 years (2015-10-20)||57.34%|
Valuing AbbVie stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AbbVie's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AbbVie's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, AbbVie shares trade at around 19x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
AbbVie's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2788. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AbbVie's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
AbbVie's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$16.7 billion.
The EBITDA is a measure of a AbbVie's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$36.2 billion|
|Operating margin TTM||37.55%|
|Gross profit TTM||USD$25.8 billion|
|Return on assets TTM||8.23%|
|Return on equity TTM||225.62%|
|Market capitalisation||USD$155.9 billion|
TTM: trailing 12 months
There are currently 12.9 million AbbVie shares held short by investors – that's known as AbbVie's "short interest". This figure is 6.4% up from 12.2 million last month.
There are a few different ways that this level of interest in shorting AbbVie shares can be evaluated.
AbbVie's "short interest ratio" (SIR) is the quantity of AbbVie shares currently shorted divided by the average quantity of AbbVie shares traded daily (recently around 8.0 million). AbbVie's SIR currently stands at 1.62. In other words for every 100,000 AbbVie shares traded daily on the market, roughly 1620 shares are currently held short.
However AbbVie's short interest can also be evaluated against the total number of AbbVie shares, or, against the total number of tradable AbbVie shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AbbVie's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 AbbVie shares in existence, roughly 10 shares are currently held short) or 0.0073% of the tradable shares (for every 100,000 tradable AbbVie shares, roughly 7 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against AbbVie.
Find out more about how you can short AbbVie stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like AbbVie.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 34.86
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and AbbVie's overall score of 34.86 (as at 10/01/2020) is pretty weak – landing it in it in the 66th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like AbbVie is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 4.96/100
AbbVie's environmental score of 4.96 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that AbbVie is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 22.65/100
AbbVie's social score of 22.65 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that AbbVie is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 16.25/100
AbbVie's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that AbbVie is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. AbbVie scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that AbbVie hasn't always managed to keep its nose clean.
|Total ESG score||34.86|
|Total ESG percentile||65.78|
|Environmental score percentile||7|
|Social score percentile||7|
|Governance score percentile||7|
|Level of controversy||3|
Dividend payout ratio: 50.75% of net profits
Recently AbbVie has paid out, on average, around 50.75% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 5.34% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), AbbVie shareholders could enjoy a 5.34% return on their shares, in the form of dividend payments. In AbbVie's case, that would currently equate to about $4.72 per share.
AbbVie's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
AbbVie's most recent dividend payout was on 16 November 2020. The latest dividend was paid out to all shareholders who bought their shares by 14 October 2020 (the "ex-dividend date").
Over the last 12 months, AbbVie's shares have ranged in value from as little as $62.55 up to $101.28. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while AbbVie's is 0.7066. This would suggest that AbbVie's shares are less volatile than average (for this exchange).
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.